tiprankstipranks
Advertisement
Advertisement

HK:2591 Stock Latest News

Guangzhou Innogen Sets 2026 AGM to Approve 2025 Results and Board Re-elections
Company AnnouncementsGuangzhou Innogen Sets 2026 AGM to Approve 2025 Results and Board Re-elections
9d ago
2591
Guangzhou Innogen Proposes New Share Award Scheme to Strengthen Incentives
PremiumCompany Announcements
Guangzhou Innogen Proposes New Share Award Scheme to Strengthen Incentives
13d ago
2591
Guangzhou Innogen Seeks Board Re-Election and Governance Updates
PremiumCompany Announcements
Guangzhou Innogen Seeks Board Re-Election and Governance Updates
13d ago
2591
Innogen Deepens Metabolic Focus as Efsubaglutide Launch Drives First Revenue but Widens Loss
PremiumCompany Announcements
Innogen Deepens Metabolic Focus as Efsubaglutide Launch Drives First Revenue but Widens Loss
3M ago
2591
Guangzhou Innogen Reshapes Company Secretariat and Secures HKEX Compliance Waiver
PremiumCompany Announcements
Guangzhou Innogen Reshapes Company Secretariat and Secures HKEX Compliance Waiver
3M ago
2591
Guangzhou Innogen Warns of Wider 2025 Loss Despite Revenue From New Diabetes Drug
PremiumCompany AnnouncementsGuangzhou Innogen Warns of Wider 2025 Loss Despite Revenue From New Diabetes Drug
3M ago
2591
Guangzhou Innogen Seeks Full H-Share Circulation via Conversion of Domestic Shares
Premium
Company Announcements
Guangzhou Innogen Seeks Full H-Share Circulation via Conversion of Domestic Shares
3M ago
2591
Guangzhou Innogen Pharma Reshapes Company Secretarial Team with New Joint Appointment and Listing Rules Waiver
Premium
Company Announcements
Guangzhou Innogen Pharma Reshapes Company Secretarial Team with New Joint Appointment and Listing Rules Waiver
4M ago
2591
Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa
PremiumCompany Announcements
Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa
4M ago
2591
Guangzhou Innogen Updates Corporate Articles Following H Share Listing
PremiumCompany Announcements
Guangzhou Innogen Updates Corporate Articles Following H Share Listing
6M ago
2591
Guangzhou Innogen Pharmaceutical Joins Stock Connect Programs
PremiumCompany Announcements
Guangzhou Innogen Pharmaceutical Joins Stock Connect Programs
6M ago
2591
Guangzhou Innogen’s Efsubaglutide Alfa Gains National Reimbursement Approval
PremiumCompany Announcements
Guangzhou Innogen’s Efsubaglutide Alfa Gains National Reimbursement Approval
6M ago
2591
Guangzhou Innogen Enhances Treasury Management with New Bank Subscription
PremiumCompany AnnouncementsGuangzhou Innogen Enhances Treasury Management with New Bank Subscription
7M ago
2591
Guangzhou Innogen Postpones Board and Supervisory Committee Re-Election
Premium
Company Announcements
Guangzhou Innogen Postpones Board and Supervisory Committee Re-Election
7M ago
2591
Guangzhou Innogen Pharmaceutical Group Invests in Structured Deposit for Treasury Management
Premium
Company Announcements
Guangzhou Innogen Pharmaceutical Group Invests in Structured Deposit for Treasury Management
7M ago
2591
Guangzhou Innogen Invests in Structured Deposit for Treasury Management
PremiumCompany Announcements
Guangzhou Innogen Invests in Structured Deposit for Treasury Management
8M ago
2591
Guangzhou Innogen Advances Phase III Trial for Obesity Treatment
PremiumCompany Announcements
Guangzhou Innogen Advances Phase III Trial for Obesity Treatment
9M ago
2591
Guangzhou Innogen Launches Diabetes Treatment in Macau
PremiumCompany Announcements
Guangzhou Innogen Launches Diabetes Treatment in Macau
9M ago
2591
Guangzhou Innogen Expands Treasury Management with New Structured Deposits
PremiumCompany Announcements
Guangzhou Innogen Expands Treasury Management with New Structured Deposits
10M ago
2591
Guangzhou Innogen Reports Increased Revenue but Faces Losses in H1 2025
PremiumCompany AnnouncementsGuangzhou Innogen Reports Increased Revenue but Faces Losses in H1 2025
10M ago
2591
Guangzhou Innogen Advances Phase II Clinical Trial for Obesity Treatment in Australia
Premium
Company Announcements
Guangzhou Innogen Advances Phase II Clinical Trial for Obesity Treatment in Australia
10M ago
2591
Guangzhou Innogen Schedules Board Meeting to Review Interim Results
Premium
Company Announcements
Guangzhou Innogen Schedules Board Meeting to Review Interim Results
10M ago
2591

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >